Slowing Progression of Chronic Kidney Disease Through Value-Based Care is organized by i3 Health and will be held from Dec 21, 2023 - Dec 20, 2024.
Module 1: 45 minutes
STATEMENT OF NEED:
Approximately 37 million people in the United States are estimated to have chronic kidney disease (CKD), a condition in which the kidneys are unable to filter blood properly, leading to the accumulation of waste and excess fluid in the body. Patients may experience heart disease, stroke, anemia, and infections, along with the risk of kidney failure and the need for dialysis or kidney transplant if the disease is left untreated and progresses to end-stage renal disease (ESRD). In addition to significant health-related consequences, patients with CKD may face substantial financial toxicity. In 2019, overall Medicare costs for patients with CKD reached $87.2 billion, equating to $24,453 per Medicare beneficiary over 65 years old. For patients with kidney failure or ESRD, Medicare fee-for-service spending, including prescription drugs, totaled $37.3 billion, or $86,400 per person (CDC, 2022). To optimize the treatment and care of patients with CKD, it is vital to not only understand the efficacy and safety of novel therapies for slowing kidney function decline, but also to utilize approaches that maximize collaboration between payers and providers. In Module 1 of this activity, Jeff Sperry, PharmD, BCPS, Clinical Pharmacist at UCHealth Memorial Hospital, will explore risk factors contributing to CKD, efficacy and safety of novel therapies for slowing kidney function decline, and evidence-based strategies for management of CKD complications.
LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to
- Identify risk factors that contribute to CKD
- Appraise the efficacy and safety of novel therapies indicated to slow kidney function decline
- Evaluate evidence-based strategies for the management of common CKD complications
Module 2: 45 minutes
STATEMENT OF NEED
Approximately 37 million people in the United States are estimated to have chronic kidney disease (CKD), a condition in which the kidneys are unable to filter blood properly, leading to the accumulation of waste and excess fluid in the body. Patients may experience heart disease, stroke, anemia, and infections, along with the risk of kidney failure and the need for dialysis or kidney transplant if the disease is left untreated and progresses to end-stage renal disease (ESRD). In addition to significant health-related consequences, patients with CKD may face substantial financial toxicity. In 2019, overall Medicare costs for patients with CKD reached $87.2 billion, equating to $24,453 per Medicare beneficiary over 65 years old. For patients with kidney failure or ESRD, Medicare fee-for-service spending, including prescription drugs, totaled $37.3 billion, or $86,400 per person (CDC, 2022). To optimize the treatment and care of patients with CKD, it is vital to not only understand the efficacy and safety of novel therapies for slowing kidney function decline, but also to utilize approaches that maximize collaboration between payers and providers. In this activity, Justin J. Bioc, PharmD, BCPS, BCGP, RPh, Head of Clinical Pharmacy at Devoted Health, will explore the cost-effectiveness of novel therapies indicated to slow kidney function decline and strategies that maximize collaboration between payers and providers to optimize the care of patients with CKD.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to:
- Compare the cost effectiveness of novel therapies indicated to slow kidney function decline
- Utilize strategies that maximize collaboration between payers and providers to optimize the care of patients with CKD
This two module CPE activity brings two leading pharmacists together to discuss the slowing progression of Chronic Kidney disease through value-based care.
In Module 1 of this activity, Jeff Sperry, PharmD, BCPS, Clinical Pharmacist at UCHealth Memorial Hospital, will explore risk factors contributing to CKD, efficacy and safety of novel therapies for slowing kidney function decline, and evidence-based strategies for management of CKD complications.
In Module 2 Justin J. Bioc, PharmD, BCPS, BCGP, RPh, Head of Clinical Pharmacy at Devoted Health, will explore the cost-effectiveness of novel therapies indicated to slow kidney function decline and strategies that maximize collaboration between payers and providers to optimize the care of patients with CKD.